Regulators in Canada recently announced that they were investigating reports of liver injuries potentially associated with the new-generation blood thinner. In 23 of those cases, Xarelto was the sole drug used in 23 of the episodes noted in the WHO database.
Health Canada has not been able to set up a clear connection between the utilization of Xarelto and the reported liver injuries. For the time being, the regulator is supporting the reporting of liver-related harmful effects that may be linked to the use of Xarelto, and certainly will continue to track the drug to identify and evaluate possible harms. Health Canada also noted that Xarelto’s Canadian prescribing information explains the medication shouldn’t be taken by individuals who have liver disease linked to difficulties with blood clotting, and have a risk of bleeding.
These Xarelto Lawsuit cases comprise more than 1,200 that are pending in a federal multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana.( (In Re: Xarelto Products Liability Litigation, No. 2592) At least 382 claims have been filed in a mass tort litigation moving forward in Pennsylvania’s Philadelphia Court of Common Pleas. (In Re: Xarelto Litigation, Case ID 150102349)
All of these criticisms accuse Xarelto’s makers of failing to warn patients about its possible risks, and maintain the drug’s sales were driven by marketing claims that positioned the drugs as a superior alternative to warfarin, a blood thinner that’s been in the marketplace for decades. Among other things, suits point out that internal hemorrhaging connected with warfarin could be stopped via the administration of vitamin K.